Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D498/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/4965—Non-condensed pyrazines
  • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/50—Pyridazines; Hydrogenated pyridazines
  • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
  • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/62—Oxygen or sulfur atoms
  • C07D213/63—One oxygen atom
  • C07D213/64—One oxygen atom attached in position 2 or 6
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/62—Oxygen or sulfur atoms
  • C07D213/69—Two or more oxygen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/62—Oxygen or sulfur atoms
  • C07D213/70—Sulfur atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/72—Nitrogen atoms
  • C07D213/73—Unsubstituted amino or imino radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/72—Nitrogen atoms
  • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
  • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
  • C07D217/24—Oxygen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
  • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
  • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
  • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D237/14—Oxygen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
  • C07D239/52—Two oxygen atoms
  • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
  • C07D239/56—One oxygen atom and one sulfur atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
  • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
  • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
  • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D241/20—Nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/04—Ortho-condensed systems
  • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
  • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
  • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D495/04—Ortho-condensed systems

Definitions

• R is h drogen, halogen, or alkyl
• X2 is N or C-R , wherein R is hydrogen, halogen, alkyl, or alkoxy;
• X3 is N or C-R 14 , wherein R 14 is hydrogen, halogen, -CN, alkyl, cycloalkyl, or alkoxy;
• X4 is N or C-R 15 , wherein R 15 is hydrogen, halogen, alkyl, -CN, or alkoxy;
• each R 22 is independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl.
• R 6 is hydrogen, halogen, -OH, -CN, alkyl, cycloalkyl, cycloalkylalkyl, amino, alkylamino, dialkylamino, cycloalkylalkylamino, alkoxy, -S-alkyl, cycloalkylalkoxy, heterocyclyl, aralkox , heteroaryloxy, aryloxy, alkynyloxy, or -N(H)COalkyl;
• X2 is N or C-R , wherein R is hydrogen, halogen, alkyl, or alkoxy;
• R 16 is hydrogen, halogen, -N(H)COX, or -W-X, wherein W is a bond, -0-, -S-, or -NH-, and X is selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, alkynyl,
• Alkylene or "alkylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing no unsaturation and having from one to twelve carbon atoms, for example, methylene, ethylene, propylene, n-butylene, and the like.
• the alkylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond.
• the points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon in the alkylene chain or through any two carbons within the chain.
• an alkylene comprises one to eight carbon atoms (e.g., Ci-C 8 alkylene). In other embodiments, an alkylene comprises one to five carbon atoms (e.g., C 1 -C5 alkylene). In other embodiments, an alkylene comprises one to four carbon atoms (e.g., C 1 -C 4 alkylene). In other embodiments, an alkylene comprises one to three carbon atoms (e.g., C 1 -C3 alkylene). In other embodiments, an alkylene comprises one to two carbon atoms (e.g., Ci-C 2 alkylene). In other embodiments, an alkylene comprises one carbon atom (e.g., Ci alkylene).
• an alkylene comprises five to eight carbon atoms (e.g., C 5 -Cs alkylene). In other embodiments, an alkylene comprises two to five carbon atoms (e.g., C 2 -C5 alkylene). In other embodiments, an alkylene comprises three to five carbon atoms (e.g., C3-C5 alkylene).
• aralkyl optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl
• heterocyclyl optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl
• heterocyclylalkyl optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl
• heteroaryl optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl
• heteroarylalkyl optionalally substituted with halogen, hydroxy, methoxy, or trifluoromethyl
• alkenyl refers to a radical of the formula -R d -aryl where R d is an alkenylene chain as defined above.
• the aryl part of the aralkenyl radical is optionally substituted as described above for an aryl group.
• the alkenylene chain part of the aralkenyl radical is optionally substituted as defined above for an alkenylene group.
• An unsaturated carbocyclyl is also referred to as "cycloalkenyl.”
• Examples of monocyclic cycloalkenyls include, e.g., cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl.
• Polycyclic carbocyclyl radicals include, for example, adamantyl, norbornyl (i.e.,
• carbocyclylalkynyl radical is optionally substituted as defined above for an alkynylene chain.
• heteroaryl is attached to the rest of the molecule through any atom of the ring(s).
• heteroaryls include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzindolyl, 1,3-benzodioxolyl, benzofuranyl, benzooxazolyl, benzo[d]thiazolyl, benzothiadiazolyl, benzo[3 ⁇ 4][l,4]dioxepinyl,
• Heteroarylalkyl refers to a radical of the formula -R c -heteroaryl, where R c is an alkylene chain as defined above. If the heteroaryl is a nitrogen-containing heteroaryl, the heteroaryl is optionally attached to the alkyl radical at the nitrogen atom.
• the alkylene chain of the heteroarylalkyl radical is optionally substituted as defined above for an alkylene chain.
• the heteroaryl part of the heteroarylalkyl radical is optionally substituted as defined above for a heteroaryl group.
• aryl radical may or may not be substituted and that the description includes both substituted aryl radicals and aryl radicals having no substitution.
• Prodrug is meant to indicate a compound that may be converted under
• the compounds disclosed herein have some or all of the 1H atoms replaced with H atoms.
• the methods of synthesis for deuterium-containing substituted heterocyclic derivative compounds are known in the art and include, by way of non-limiting example only, the following synthetic methods.
• X5 is C-R 5 or N
• X7 is C-R 7 or N
• X3 is N or C-R 14 , wherein R 14 is hydrogen, halogen, -CN, alkyl, cycloalkyl, or alkoxy;
• X7 is C-R 7 or N
• X4 is N or C-R 15 , wherein R 15 is hydrogen, halogen, alkyl, -CN, or alkoxy;
• Formula (la), wherein R 5 and R 8 are hydrogen.
• Another embodiment provides a compound of Formula (la), wherein R 5 , R 6 , R 7 and R 8 are hydrogen.
• Another embodiment provides a compound of Formula (la), wherein R 7 is a halogen.
• Another embodiment provides a compound of Formula (la), wherein R 6 is a halogen.
• Another embodiment provides a compound of Formula (la), wherein R 6 is a heteroaryl.
• Another embodiment provides a compound of Formula (la), wherein R 6 is an aryl.
• Another embodiment provides a compound of Formula (la), wherein R 6 is an alkyl.
• Another embodiment provides a compound of Formula (la), wherein R 6 is an aryl.
• Another embodiment provides a compound of Formula (la), wherein R 5 and
• One embodiment provides a compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (lb), Formula (lb)
• X5 is C-H
• X8 is C-H
• R 6 is hydrogen, or halogen
• R 7 is hydrogen, or halogen
• X2 is C-H
• Y is selected from a bond, or -CH 2 -;
• Z is selected from -S0 2 R 21 , -N(R 22 )S0 2 R 21 , -S0 2 N(R 22 ) 2 , -N(R 22 )S0 2 N(R 22 ) 2 , -CON(R 22 ) 2 , N(R 22 )C0 2 R 21 , -N(R 22 )CON(R 22 ) 2 , -N(R 22 )COR 21 , -OC(0)N(R 22 ) 2 , -OS0 2 N(R 22 ) 2 , or - N(R 22 )S0 3 R 21 ;
• X3 is C-R 14 , wherein R 14 is hydrogen, halogen, Ci-C 3 alkyl, or Ci-C 3 alkoxy;
• X4 is C-R 15 , wherein R 15 is hydrogen, or halogen;
• R 16 is -W-X, wherein W is a bond, -0-, -S-, or -NH-, and X is selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• each R 22 is independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl.
• Another embodiment provides a compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (lb), wherein R 6 is halogen, and R 7 is hydrogen.
• Another embodiment provides a compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (lb), wherein R 6 is hydrogen, and R 7 is halogen.
• Another embodiment provides a compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (lb), wherein R 6 is hydrogen, and R 7 is hydrogen.
• Another embodiment provides a compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (lb), wherein Y is -CH 2 -.
• Another embodiment provides a compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (lb), wherein Y is -CH 2 -, and Z is -S0 2 R 21 , or -N(R 22 )S0 2 R 21 .
• Another embodiment provides a compound, or a pharmaceutically acceptable salt thereof, having the
• Another embodiment provides a compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (lb), wherein Y is a bond.
• Another embodiment provides a compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (lb), wherein Y is a bond, and Z is -N(R 22 )S0 2 R 21 , or -N(R 22 )S0 2 N(R 22 ) 2 .
• Another embodiment provides a compound, or a pharmaceutically acceptable salt thereof, having the
• heterocyclylalkyl Another embodiment provides a compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (lb), wherein Y is a bond, Z is -
• Another embodiment provides a compound, or a pharmaceutically acceptable salt
• Another embodiment provides a compound, or a pharmaceutically acceptable salt
• R is alkyl, cycloalkyl, or aralkyl.
• Another embodiment provides a compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (lb), wherein X is alkyl.
• Another embodiment provides a compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (lb), wherein W is -NH-, and X is alkyl.
• Another embodiment provides a compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (lb), wherein W is -O- and X is alkyl.
• Another embodiment provides a compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (lb), wherein W is a bond, and X is alkyl.
• Another embodiment provides a compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (lb), wherein X is cycloalkylalkyl.
• Another embodiment provides a compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (lb), wherein W is -NH-, and X is cycloalkylalkyl.
• Another embodiment provides a compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (lb), wherein W is -O- and X is cycloalkylalkyl.
• Another embodiment provides a compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (lb), wherein W is a bond, and X is cycloalkylalkyl.
• Another embodiment provides a compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (lb), wherein X is aryl.
• Another embodiment provides a compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (lb), wherein W is -NH-, and X is aryl.
• Another embodiment provides a compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (lb), wherein W is -0-, and X is aryl.
• Another embodiment provides a compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (lb), wherein W is a bond, and X is aryl.
• Another embodiment provides a compound, or a pharmaceutically acceptable salt
• Z is -S0 2 R
• W is -0-
• X is cycloalkylalkyl
• X6 is C-H or N
• X2 is N or C-R , wherein R is hydrogen, halogen, alkyl, or alkoxy; R is -Y-Z;
• Y is selected from a bond, -CH 2 -, or -CH(Ci-C 4 alkyl)-;
• X4 is N or C-R 15 , wherein R 15 is hydrogen, halogen, -CN, alkyl, alkoxy, aryloxy, aralkyloxy, cycloalkylalkyloxy, heterocyclyloxy, heteroarylalkyloxy, or alkynyloxy;
• cycloalkylalkynyl heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl
• each R 21 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• One embodiment provides a compound of Formula (Ha), or a pharmaceutically acceptable salt thereof,
• X5 is C-R 5 or N; provided that if X6 is N, then X5 is C-R 5 , and if X5 is N, then X6 is CH; R 5 is hydrogen, halogen, -OH,-CN, -OR 61 , -NHR 61 , -N(R 61 ) 2 , alkyl, cycloalkyl,
• ring B is an optionally substituted 5- or 6-membered heterocyclic ring containing at least one oxygen or nitrogen atom;
• Formula (III), wherein R is alkyl.
• Another embodiment provides a compound of Formula (III), wherein R 14 is hydrogen, halogen, or alkyl.
• Another embodiment provides a compound of Formula (III), wherein X4 is C-R 15 .
• Another embodiment provides a compound of Formula (III), wherein W is -0-.
• Another embodiment provides a compound of Formula (III), wherein W is -NH-.
• Another embodiment provides a compound of Formula (III), wherein X is alkyl.
• Another embodiment provides a compound of Formula (III), wherein X is alkynyl.
• Another embodiment provides a compound of Formula (III), wherein X is aryl.
• Another embodiment provides a compound of Formula (III), wherein X is cycloalkylalkyl.
• Another embodiment provides a compound of Formula (III), wherein X is cycloalkylalkyl.
• Another embodiment provides a compound of Formula (III), wherein X is cyclo
• One embodiment provides a compound of Formula (IV), or a
• R 16 is hydrogen, halogen, or -W-X, wherein W is a bond, -0-, -S-, or -NH-, and X is selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl,
• heterocyclylalkyl heteroaryl, or heteroarylalkyl
• each R 21 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• Another embodiment provides a compound of Formula (V), or a
• R 2 is selected from CH 3 , CH 2 CH 3 , CH 2 CF 3 , CH 2 F, CHF 2 , CF 3 , CH 2 D, CHD 2 , or CD 3 ;
• X5 is C-R 5 or N
• X7 is C-R 7 or N
• each R 61 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• each R 61 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• R 7 is hydrogen, halogen, -OH,-CN, -OR 61 , -NHR 61 , -N(R 61 ) 2 , alkyl, cycloalkyl,
• R 13 is -Y-Z
• X3 is N or C-R 14 , wherein R 14 is hydrogen, halogen, alkyl, cycloalkyl, or alkoxy;
• X4 is N or C-R 15 , wherein R 15 is hydrogen, halogen, alkyl, or alkoxy; R is hydrogen, halogen, or -W-X, wherein W is a bond, -0-, -S-, or -NH-, and X is selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl,
• Another embodiment provides a compound of Formula (V), wherein X5 is N. Another embodiment provides a compound of Formula (V), wherein X6 is N. Another embodiment provides a compound of Formula (V), wherein X7 is N. Another embodiment provides a compound of Formula (V), wherein X8 is N. Another embodiment provides a compound of Formula (V), wherein none of X5, X6, X7, or X8 is N. Another embodiment provides a compound of Formula (V), wherein R 5 andR 8 are hydrogen. Another embodiment provides a compound of Formula (V), wherein R 5 , R 6 , R 7 and R 8 are hydrogen. Another embodiment provides a compound of Formula (V), wherein R 7 is a halogen.
• Another embodiment provides a compound of Formula (V), wherein Z is -S0 2 R .
• Another embodiment provides a compound of Formula (V), wherein Z is -N(R 22 )S0 2 R 21.
• Another embodiment provides a compound of Formula (V), wherein Z is -S0 2 N(R 22 ) 2 .
• Another embodiment provides a compound of Formula (V), wherein Z is -N(R )CON(R ) 2 .
• R 2 is CH 3 or CD 3 ;
• R is -Y-Z
• Z is -S0 2 R 21 ;
• each R 21 is CH 3 or CH 2 CH 3 .
• R 2 is CH 3 or CD 3 ;
• R 5 is hydrogen or CH 3 ;
• R 14 is hydrogen, F, or CI
• R 16 is -W-X, wherein W is -O- or -NH-, and X is selected from CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , CH(CH ) 2 , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, CH 2 -(cyclopropyl), C 6 H5, 4- fluoro(C 6 H 4 ), 2,4-difluoro(C 6 H ), 2-fluoro(C 6 H 4 ), 4-tetrahydropyranyl, 3-tetrahydropyranyl, oxolan-3-yl, 4,4-difluorocyclohexyl, and 4-hydroxycyclohexyl; and
• each R 21 is CH 3 or CH 2 CH 3 .
• R 5 is hydrogen or CH ;
• R 6 is hydrogen, CH 3 , CI, F, Br, NH 2 , N(CH 3 ) 2 , NH(alkyl), or CD 3 ;
• Y is selected from a bond or -CH 2 -;
• R 5 is hydrogen or CH ;
• R 6 is hydrogen, CH 3 , CI, F, Br, NH 2 , N(CH 3 ) 2 , NH(alkyl), or CD 3 ;
• each R 21 is CH 3 or CH 2 CH 3 .
• One embodiment provides a compound of Formula (Vie), or a pharmaceutically acce table salt thereof,
• R is hydrogen, CH 3 , or CHF 2 ;
• X9 is N or CH
• R 16 is -W-X, wherein W is -O- or -NH-, and X is selected from CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , CH 2 -(cyclopropyl), CH 2 CH 2 CFH 2 , 2,4-difiuoro(C 6 H 3 ), 2,3-difiuoro(C 6 H 3 ), 2-chloro-4- fluoro(C 6 H 3 ), 2-fluoro(C 6 H 4 ), and 2-chloro(C 6 H 4 ); and
• One embodiment provides a compound of Formula (VII), or a
• X5 is C-R 5 or N; provided that if X6 is N, then X5 is C-R 5 , and if X5 is N, then X6 is CH; R 5 is hydrogen, halogen, -OH,-CN, -OR 61 , -NHR 61 , -N(R 61 ) 2 , alkyl, cycloalkyl,
• cycloalkylalkynyl amino, alkylamino, dialkylamino, heterocyclyl, cycloalkylalkylamino, alkox , cycloalkyloxy, cycloalkylalkoxy, alkyl-S-, cycloalkyl-S-, and cycloalkylalkyl-S-;
• R 13 is -Y-Z
• Z is selected from -S0 2 R 21 , -N(R 22 )S0 2 R 21 , -S0 2 N(R 22 ) 2 , -N(R 22 )S0 2 N(R 22 ) 2 , -CON(R 22 ) 2 , - N(R 22 )C0 2 R 21 , -N(R 22 )CON(R 22 ) 2 , -N(R 22 )COR 21 , -OC(0)N(R 22 ) 2 , -OS0 2 N(R 22 ) 2 , or - N(R 22 )S0 3 R 21 ;
• X3 is N or C-R 14 , wherein R 14 is hydrogen, halogen, -CN, alkyl, cycloalkyl, or alkoxy; or optionally when X4 is C-R 15 , R 14 and R 15 connect to form a ring;
• X4 is N or C-R 15 , wherein R 15 is hydrogen, halogen, -CN, alkyl, or alkoxy;
• R 16 is hydrogen, halogen, or -W-X, wherein W is a bond, -0-, -S-, or -NH-, and X is selected from alkyl, alkynyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkynyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl; or optionally when X4 is C-
• R 15 , R 16 and R 15 connect to form a ring
• each R 21 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• each R 22 is independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl.
• Another embodiment provides a compound of Formula (VII), wherein X3 is N. Another embodiment provides a compound of Formula (VII), wherein X4 is N. Another embodiment provides a compound of Formula (VII), wherein X2 and X3 are N. Another embodiment provides a compound of Formula (VII), wherein X2 is C-R 12 , X3 is C-R 14 , and X4 is C-R 15 .
• Another embodiment provides a compound of Formula (VII), wherein R is CH 3 . Another embodiment provides a compound of Formula (VII), wherein X6 is C-H. Another embodiment provides a compound of Formula (VII), wherein X6 is N. Another embodiment provides a compound of Formula (VII), wherein X5 is C-R 5 . Another embodiment provides a compound of Formula (VII), wherein X5 is N. Another embodiment provides a compound of Formula (VII), wherein R 5 is hydrogen, halogen, or alkyl. Another embodiment provides a compound of Formula (VII), wherein R 6 is hydrogen, halogen, or alkyl. Another embodiment provides a compound of Formula (VII), wherein R 6 is heterocyclyl. Another embodiment provides a compound of Formula (VII), wherein R 6 is cycloalkylalkynyl. Another embodiment provides a compound of Formula (VII), wherein R 6 is cycloalkylalkynyl. Another embodiment provides a compound of Formula (VII),
• embodiment provides a compound of Formula (VII), wherein R 6 is alkoxy, cycloalkyloxy, or cycloalkylalkoxy.
• Another embodiment provides a compound of Formula (VII), wherein Y is a bond.
• Another embodiment provides a compound of Formula (VII), wherein Y is a -CH 2 -.
• Another embodiment provides a compound of Formula (VII), wherein Z is -CON(R 22 ) 2 .
• Another embodiment provides a compound of Formula (VII), wherein R is alkyl, cycloalkyl, or cycloalkylalkyl. Another embodiment provides a compound of
• Formula (VII), wherein R 21 is alkyl.
• Another embodiment provides a compound of Formula (VII), wherein R 14 is hydrogen, halogen, or alkyl.
• Another embodiment provides a compound of Formula (VII), wherein X4 is C-R 15 .
• Another embodiment provides a compound of Formula (VII), wherein W is -0-.
• Another embodiment provides a compound of Formula (VII), wherein W is -NH-.
• Another embodiment provides a compound of Formula (VII), wherein X is alkyl.
• Another embodiment provides a compound of Formula (VII), wherein X is alkynyl.
• Another embodiment provides a compound of Formula (VII), wherein X is aryl.
• Another embodiment provides a compound of Formula (VII), wherein X is cycloalkylalkyl. Another embodiment provides a compound of Formula (VII), wherein X is cycloalkylalkynyl. Another embodiment provides a compound of Formula (VII), wherein W is -O- and X is alkyl. Another embodiment provides a compound of Formula (VII), wherein W is -O- and X is alkynyl. Another embodiment provides a compound of Formula (VII), wherein W is -O- and X is aryl. Another embodiment provides a compound of Formula (VII), wherein W is -O- and X is cycloalkylalkyl. Another embodiment provides a compound of Formula (VII), wherein W is -O- and X is cycloalkylalkynyl. Another embodiment provides a compound of Formula (VII), wherein the R 6 is CD 3 .
• X6 is C-H or N
• R 6 is hydrogen, halogen, -OH,-CN, alkyl, alkynyl, cycloalkyl, cycloalkylalkyl,
• cycloalkylalkynyl amino, alkylamino, dialkylamino, heterocyclyl, cycloalkylalkylamino, alkoxy, cycloalkyloxy, cycloalkylalkoxy, alkyl-S-, cycloalkyl-S-, and cycloalkylalkyl-S-;
• R 13 is -Y-Z
• Y is selected from a bond, -CH 2 -, or -CH(Ci-C4 alkyl)-;
• Z is selected from -N(R 22 )S0 2 R 21 , -N(R 22 )C0 2 R 21 , -N(R 22 )COR 21 , or -N(R 22 )S0 3 R 21 ;
• X4 is N or C-R 15 , wherein R 15 is hydrogen, halogen, -CN, alkyl, or alkoxy;
• R 16 is hydrogen, halogen, or -W-X, wherein W is a bond, -0-, -S-, or -NH-, and X is selected from alkyl, alkynyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkynyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl; or optionally when X4 is C-
• R 15 , R 16 and R 15 connect to form a ring
• each R 21 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl; or optionally when R 21 and
• Another embodiment provides a compound of Formula (Vila), wherein R is CH 3 .
• Another embodiment provides a compound of Formula (Vila), wherein X6 is C-H.
• Another embodiment provides a compound of Formula (Vila), wherein X6 is N.
• Another embodiment provides a compound of Formula (Vila), wherein X5 is C-R 5 .
• Another embodiment provides a compound of Formula (Vila), wherein X5 is N.
• Another embodiment provides a compound of Formula (Vila), wherein R 5 is hydrogen, halogen, or alkyl.
• Another embodiment provides a compound of Formula (Vila, wherein R 6 is hydrogen, halogen, or alkyl.
• Another embodiment provides a compound of Formula (Vila), wherein R 6 is heterocyclyl.
• Another embodiment provides a compound of Formula (Vila), wherein R 6 is cycloalkylalkynyl.
• Another embodiment provides a compound of Formula (Vila), wherein R 6 is alkoxy, cycloalkyloxy, or cycloalkylalkoxy.
• Another embodiment provides a compound of Formula (Vila), wherein Y is a bond.
• Another embodiment provides a compound of Formula (Vila), wherein Y is a -CH 2 -.
• Another embodiment provides a compound of Formula (Vila), wherein Z is -N(R 22 )S0 2 R 21.
• Another embodiment provides a compound of Formula (Vila), wherein Z is -N(R 22 )C0 2 R 21.
• Another embodiment provides a compound of Formula (Vila), wherein R 21 is alkyl, cycloalkyl, or cycloalkylalkyl. Another embodiment provides a compound of Formula (Vila), wherein R 21 is alkyl. Another embodiment provides a compound of Formula (Vila), wherein
• R 22 is alkyl. Another embodiment provides a compound of Formula (Vila), wherein both R 21 and R 22 are alkyl and connect to form a ring. Another embodiment provides a compound of Formula (Vila), wherein R 14 is hydrogen, halogen, or alkyl. Another embodiment provides a compound of Formula (Vila), wherein X4 is C-R 15 . Another embodiment provides a compound of Formula (Vila), wherein W is -0-. Another embodiment provides a compound of Formula (Vila), wherein W is -NH-. Another embodiment provides a compound of Formula (Vila), wherein X is alkyl. Another embodiment provides a compound of Formula (Vila), wherein X is alkynyl.
• Another embodiment provides a compound of Formula (Vila), wherein X is aryl. Another embodiment provides a compound of Formula (Vila), wherein X is cycloalkylalkyl. Another embodiment provides a compound of Formula (Vila), wherein X is cycloalkylalkynyl. Another embodiment provides a compound of Formula (Vila), wherein W is -O- and X is alkyl. Another embodiment provides a compound of Formula (Vila), wherein W is -O- and X is alkynyl. Another embodiment provides a compound of Formula (Vila), wherein W is -O- and X is aryl.
• Another embodiment provides a compound of Formula (Vila), wherein W is -O- and X is cycloalkylalkyl. Another embodiment provides a compound of Formula (Vila), wherein W is -O- and X is cycloalkylalkynyl. Another embodiment provides a compound of Formula (Vila), wherein the R 6 is CD 3 .
• R 2 is selected from CH 3 , CH 2 CH 3 , CH 2 CF 3 , CH 2 F, CHF 2 , CF 3 , CH 2 D, CHD 2 , or CD 3 ;
• X5 is C-R 5 or N
• X6 is C-R 6 or N
• X7 is C-R 7 or N
• X8 is C-R or N; wherein no more than two of X5, X6, X7, or X8 may be N;
• R 5 is hydrogen, halogen, -OH,-CN, -OR 61 , -NHR 61 , -N(R 61 ) 2 , alkyl, cycloalkyl,
• each R 61 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• R 6 is hydrogen, halogen, -OH,-CN, -OR 61 , -NHR 61 , -N(R 61 ) 2 , alkyl, cycloalkyl,
• each R 61 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• each R 61 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• Y is selected from a bond, -CH 2 -, or -CH(Ci-C 4 alkyl)-;
• X3 is N or C-R 14 , wherein R 14 is hydrogen, halogen, -CN, alkyl, cycloalkyl, or alkoxy; or optionally when X4 is C-R 15 , R 14 and R 15 connect to form a ring;
• X4 is N or C-R 15 , wherein R 15 is hydrogen, halogen, -CN, alkyl, or alkoxy;
• R 16 is hydrogen, halogen, or -W-X, wherein W is a bond, -0-, -S-, or -NH-, and X is selected from alkyl, alkynyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkynyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl; or optionally when X4 is C-
• R 15 , R 16 and R 15 connect to form a ring
• each R 21 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• Another embodiment provides a compound of Formula (VIII), wherein R is CH 3 . Another embodiment provides a compound of Formula (VIII), wherein R is CD 3 . Another embodiment provides a compound of Formula (VIII), wherein X5 is N. Another embodiment provides a compound of Formula (VIII), wherein X6 is N. Another
• embodiment provides a compound of Formula (VIII), wherein none of X5, X6, X7, or X8 is
• Another embodiment provides a compound of Formula (VIII), wherein R and R are hydrogen. Another embodiment provides a compound of Formula (VIII), wherein R 5 , R 6 , R 7
• R are hydrogen.
• Another embodiment provides a compound of Formula (VIII), wherein R 7 is a halogen.
• Another embodiment provides a compound of Formula (VIII), wherein R 6 is a halogen.
• Another embodiment provides a compound of Formula (VIII), wherein R 6 is a heteroaryl.
• Another embodiment provides a compound of Formula (VIII), wherein R 6 is an aryl.
• Another embodiment provides a compound of Formula (VIII), wherein R 6 is an alkyl.
• Another embodiment provides a compound of Formula (VIII), wherein R 6 is an aryl.
• Another embodiment provides a compound of Formula (VIII), wherein Y is a bond. Another embodiment provides a compound of Formula (VIII), wherein Y is a -CH 2 -. Another embodiment provides a compound of Formula (VIII), wherein Z is -S0 2 R .
• Another embodiment provides a compound of Formula (VIII), wherein Z is -N(R )S0 2 R .
• Another embodiment provides a compound of Formula (VIII), wherein Z is -S0 2 N(R ) 2 .
• Another embodiment provides a compound of Formula (VIII), wherein Z is -
• Another embodiment provides a compound of Formula (VIII), wherein Z is -
• R 21 is alkyl, cycloalkyl, or cycloalkylalkyl. Another embodiment provides a compound of
• Another embodiment provides a compound of Formula (VIII), wherein W is -O- and X is alkyl. Another embodiment provides a compound of Formula (VIII), wherein W is -O- and X is aryl. Another embodiment provides a compound of Formula (VIII), wherein W is -O- and X is cycloalkylalkyl. Another embodiment provides a compound of Formula (VIII), wherein R 5 andR 8 are hydrogen. Another embodiment provides a compound of Formula (VIII), wherein R 5 and R 8 are hydrogen, and R 6 is heteroaryl.
• R 2 is selected from CH 3 , CH 2 CH 3 , CH 2 CF 3 , CH 2 F, CHF 2 , CF 3 , CH 2 D, CHD 2 , or CD 3 ;
• X5 is C-R 5 or N
• X6 is C-R 6 or N
• X7 is C-R 7 or N
• X8 is C-R or N; wherein no more than two of X5, X6, X7, or X8 may be N;
• R 5 is hydrogen, halogen, -OH,-CN, -OR 61 , -NHR 61 , -N(R 61 ) 2 , alkyl, cycloalkyl,
• each R 61 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• R 6 is hydrogen, halogen, -OH,-CN, -OR 61 , -NHR 61 , -N(R 61 ) 2 , alkyl, cycloalkyl,
• each R 61 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• each R 61 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• X2 is N or C-R 12 , wherein R 12 is hydrogen, halogen, alkyl, or alkoxy;
• R 13 is -Y-Z
• Y is selected from a bond, -CH 2 -, or -CH(Ci-C 4 alkyl)-;
• Z is selected from -N(R 22 )S0 2 R 21 , -N(R 22 )C0 2 R 21 , -N(R 22 )COR 21 , or -N(R 22 )S0 3 R 21 ;
• X3 is N or C-R 14 , wherein R 14 is hydrogen, halogen, -CN, alkyl, cycloalkyl, or alkoxy; or optionally when X4 is C-R 15 , R 14 and R 15 connect to form a ring;
• X4 is N or C-R 15 , wherein R 15 is hydrogen, halogen, -CN, alkyl, or alkoxy;
• R 15 , R 16 and R 15 connect to form a ring
• each R 21 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl; or optionally when R 21 and
• R 22 are alkyl, R 21 and R 22 connect to form a ring;
• each R 22 is independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl.
• Another embodiment provides a compound of Formula (Villa), wherein R is
• Another embodiment provides a compound of Formula (Villa), wherein R is CD 3 .
• Another embodiment provides a compound of Formula (Villa), wherein X5 is N.
• Another embodiment provides a compound of Formula (Villa), wherein X6 is N.
• embodiment provides a compound of Formula (Villa), wherein X7 is N.
• embodiment provides a compound of Formula (Villa), wherein X8 is N.
• Another embodiment provides a compound of Formula (Villa), wherein R 5 and R 8 are hydrogen.
• Another embodiment provides a compound of Formula (Villa), wherein R 5 , R 6 ,
• Y is selected from a bond, -CH 2 -, or -CH(Ci-C4 alkyl)-;
• X3 is N or C-R 14 , wherein R 14 is hydrogen, halogen, -CN, alkyl, cycloalkyl, or alkoxy; or optionally when X4 is C-R 15 , R 14 and R 15 connect to form a ring;
• X5 is C-R 5 or N
• each R 61 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• R 6 is hydrogen, halogen, -OH,-CN, -OR 61 , -NHR 61 , -N(R 61 ) 2 , alkyl, cycloalkyl,
• R 7 is hydrogen, halogen, -OH,-CN, -OR 61 , -NHR 61 , -N(R 61 ) 2 , alkyl, cycloalkyl,
• R is hydrogen, halogen, or alkyl
• X2 is N or C-R , wherein R is hydrogen, halogen, alkyl, or alkoxy;
• X4 is N or C-R , wherein R is hydrogen, halogen, alkyl, or alkoxy;
• R 16 is hydrogen, halogen, or -W-X, wherein W is a bond, -0-, -S-, or -NH-, and X is selected from alkyl, alkynyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkynyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• each R 21 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• Another embodiment provides a compound of Formula (XII), wherein R is CD 3 .
• Another embodiment provides a compound of Formula (XII), wherein X5 is N.
• Another embodiment provides a compound of Formula (XII), wherein X6 is N.
• Another embodiment provides a compound of Formula (XII), wherein X7 is N.
• Another embodiment provides a compound of Formula (XII), wherein X8 is N.
• Another embodiment provides a compound of Formula (XII), wherein none of X5, X6, X7, or X8 is N.
• Another embodiment provides a compound of Formula (XII), wherein none of X5, X6, X7, or X8 is N.
• Another embodiment provides a
• Another embodiment provides a compound of Formula (XII), wherein Z is -S0 2 R .
• Another embodiment provides a compound of Formula (XII), wherein Z is -N(R )C0 2 R .
• Another embodiment provides a compound of Formula (XII), wherein Z is -
• R J and R° are hydrogen.
• Another embodiment provides a compound of Formula (XII), wherein R 5 and R 8 are hydrogen, and R 6 is heteroaryl.
• Another embodiment provides a compound of Formula (XII), wherein R A is
• Another embodiment provides a compound of Formula (XII), wherein R is
• Another embodiment provides a compound of Formula (XII), wherein R A is
• R is selected from CH 3 , CH 2 CH 3 , CH 2 CF 3 , CH 2 F, CHF 2 , CF 3 , CH 2 D, CHD 2 , or CD 3 ;
• X6 is C-R 6 or N
• X7 is C-R 7 or N
• X8 is C-R or N; wherein no more than two of X5, X6, X7, or X8 may be N;
• each R 61 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• R 6 is hydrogen, halogen, -OH,-CN, -OR 61 , -NHR 61 , -N(R 61 ) 2 , alkyl, cycloalkyl,
• each R 61 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• R is hydrogen, halogen, or alkyl
• R is hydrogen or C 1 -C 4 alkyl
• R 13 is -Y-Z
• Y is selected from -CH 2 -, or -CH(Ci-C 4 alkyl)-;
• each R 21 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• each R 22 is independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl.
• Another embodiment provides a compound of Formula (XIII), wherein R is CH 3 . Another embodiment provides a compound of Formula (XIII), wherein R is CD 3 . Another embodiment provides a compound of Formula (XIII), wherein X5 is N. Another embodiment provides a compound of Formula (XIII), wherein X6 is N. Another
• R are hydrogen.
• Another embodiment provides a compound of Formula (XIII), wherein R 7 is a halogen.
• Another embodiment provides a compound of Formula (XIII), wherein R 6 is a halogen.
• Another embodiment provides a compound of Formula (XIII), wherein R 6 is a heteroaryl.
• Another embodiment provides a compound of Formula (XIII), wherein R 6 is an aryl.
• Another embodiment provides a compound of Formula (XIII), wherein R 6 is an alkyl.
• Another embodiment provides a compound of Formula (XIII), wherein R 6 is an aryl.
• Another embodiment provides a compound of Formula (XIII), wherein Y is a
• Another embodiment provides a compound of Formula (XIII), wherein Z is -S0 2 R .
• Another embodiment provides a compound of Formula (XIII), wherein Z is -S0 2 N(R ) 2 .
• Another embodiment provides a compound of Formula (XIII), wherein Z is -CON(R ) 2 .
• Another embodiment provides a compound of Formula (XIII), wherein R 21 is alkyl, cycloalkyl, or cycloalkylalkyl. Another embodiment provides a compound of Formula (XIII), wherein R 21 is alkyl, cycloalkyl, or cycloalkylalkyl. Another embodiment provides a compound of Formula (XIII), wherein R 21 is alkyl, cycloalkyl, or cycloalkylalkyl. Another embodiment provides a compound of Formula (XIII), wherein R 21 is alkyl, cycloalkyl, or cycloalkylalkyl. Another embodiment provides a compound of Formula (XIII), wherein R 21 is alkyl, cycloalkyl, or cycloalkylalkyl. Another embodiment provides a compound of Formula (XIII), wherein R 21 is alkyl, cycloalkyl, or cycloalkylalkyl. Another embodiment provides a compound of Formula (XIII), wherein R 21 is alkyl
• Another embodiment provides a compound of Formula (XIII), wherein W is -O- and X is cycloalkylalkyl. Another embodiment provides a compound of Formula (XIII), wherein R 5 and R 8 are hydrogen. Another embodiment provides a compound of Formula (XIII), wherein R 5 andR 8 are hydrogen, and R 6 is heteroaryl.
• One embodiment provides a compound of Formula (XIV), or a
• R 2 is CH 3 , CH 2 CH 3 , CH 2 CF 3 , CH 2 F, CHF 2 , CF 3 , CH 2 D, CHD 2 , or CD 3 ;
• X6 is C-H or N
• X5 is C-R 5 or N; provided that if X6 is N, then X5 is C-R 5 , and if X5 is N, then X6 is CH; R 5 is hydrogen, halogen, -OH,-CN, -OR 61 , -NHR 61 , -N(R 61 ) 2 , alkyl, cycloalkyl,
• R 61 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• R 6 is hydrogen, halogen, -OH,-CN, alkyl, alkynyl, cycloalkyl, cycloalkylalkyl,
• cycloalkylalkynyl amino, alkylamino, dialkylamino, heterocyclyl, cycloalkylalkylamino, alkoxy, cycloalkyloxy, cycloalkylalkoxy, alkyl-S-, cycloalkyl-S-, and cycloalkylalkyl-S-;
• R is hydrogen or C 1 -C4 alkyl
• R 13 is -Y-Z
• Y is selected from -CH 2 -, or -CH(d-C 4 alkyl)-;
• Z is selected from -S0 2 R 21 , -S0 2 N(R 22 ) 2 , or -CON(R 22 ) 2 ;
• R 15 is hydrogen, halogen or C 1 -C4 alkyl
• R 16 is hydrogen, halogen, or -W-X, wherein W is a bond, -0-, -S-, or -NH-, and X is selected from alkyl, alkynyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkynyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl; or optionally, R 16 and R 15 connect to form a ring;
• each R 21 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• each R 22 is independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl.
• Another embodiment provides a compound of Formula (XIV), wherein R is CH 3 . Another embodiment provides a compound of Formula (XIV), wherein X6 is C-H. Another embodiment provides a compound of Formula (XIV), wherein X6 is N. Another embodiment provides a compound of Formula (XIV), wherein X5 is C-R 5 . Another embodiment provides a compound of Formula (XIV), wherein X5 is N. Another embodiment provides a compound of Formula (XIV), wherein R 5 is hydrogen, halogen, or alkyl. Another embodiment provides a compound of Formula (XIV), wherein R 6 is hydrogen, halogen, or alkyl. Another embodiment provides a compound of Formula (XIV), wherein R 6 is heterocyclyl. Another embodiment provides a compound of Formula (XIV), wherein R 6 is cycloalkylalkynyl.
• Another embodiment provides a compound of Formula (XIV), wherein R 6 is alkoxy, cycloalkyloxy, or cycloalkylalkoxy.
• Another embodiment provides a compound of Formula (XIV), wherein Y is a -CH 2 -.
• R 2 is selected from CH 3 , CH 2 CH 3 , CH 2 CF 3 , CH 2 F, CHF 2 , CF 3 , CH 2 D, CHD 2 , or CD 3 ;
• XI is C-H or N;
• Another embodiment provides a compound of Formula (XV), wherein Z is -S0 2 N(R 22 ) 2 .
• Another embodiment provides a compound of Formula (XV), wherein Z is -
• X6 is C-R 6 or N
• X3 is N or C-R 14 , wherein R 14 is hydrogen, halogen, -CN, alkyl, cycloalkyl, or alkoxy; or optionally when X4 is C-R 15 , R 14 and R 15 connect to form a ring;
• Another embodiment provides a compound of Formula (XVI), wherein R is CD 3 . Another embodiment provides a compound of Formula (XVI), wherein X5 is N. Another embodiment provides a compound of Formula (XVI), wherein X6 is N. Another
• embodiment provides a compound of Formula (XVI), wherein none of X5, X6, X7, or X8 is
• Another embodiment provides a compound of Formula (XVI), wherein R 5 andR 8 are hydrogen. Another embodiment provides a compound of Formula (XVI), wherein R 5 , R 6 , R 7 and R are hydrogen. Another embodiment provides a compound of Formula (XVI), wherein R 7 is a halogen. Another embodiment provides a compound of Formula (XVI), wherein R 6 is a halogen. Another embodiment provides a compound of Formula (XVI), wherein R 6 is a heteroaryl. Another embodiment provides a compound of Formula (XVI), wherein R 6 is an aryl. Another embodiment provides a compound of Formula (XVI), wherein R 6 is an alkyl. Another embodiment provides a compound of Formula (XVI), wherein R 6 is an aryl.
• Another embodiment provides a compound of Formula (XVI), wherein Z is -N(R 22 )S0 2 R 21.
• Another embodiment provides a compound of Formula (XVI), wherein Z is -
• R 21 is alkyl, cycloalkyl, or cycloalkylalkyl. Another embodiment provides a compound of
• Formula (XVI), wherein R 21 is alkyl.
• Another embodiment provides a compound of Formula (XVI), wherein R 14 is hydrogen, halogen, or alkyl.
• Another embodiment provides a compound of Formula (XVI), wherein X4 is C-R 15 .
• Another embodiment provides a compound of Formula (XVI), wherein W is -0-.
• Another embodiment provides a compound of Formula (XVI), wherein W is -NH-.
• Another embodiment provides a compound of Formula (XVI), wherein X is alkyl.
• Another embodiment provides a compound of Formula (XVI), wherein X is aryl.
• Another embodiment provides a compound of Formula (XVI), wherein X is cycloalkylalkyl.
• R 2 is CH 3 , CH 2 CH 3 , CH 2 CF 3 , CH 2 F, CHF 2 , CF 3 , CH 2 D, CHD 2 , or CD 3 ;
• X6 is C-H or N
• X5 is C-R 5 or N; provided that if X6 is N, then X5 is C-R 5 , and if X5 is N, then X6 is CH; R 5 is hydrogen, halogen, -OH,-CN, -OR 61 , -NHR 61 , -N(R 61 ) 2 , alkyl, cycloalkyl,
• each R 61 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• R 6 is hydrogen, halogen, -OH,-CN, alkyl, alkynyl, cycloalkyl, cycloalkylalkyl,
• cycloalkylalkynyl amino, alkylamino, dialkylamino, heterocyclyl, cycloalkylalkylamino, alkoxy, cycloalkyloxy, cycloalkylalkoxy, alkyl-S-, cycloalkyl-S-, and cycloalkylalkyl-S-;
• X2 is N or C-R 12 , wherein R 12 is hydrogen, halogen, alkyl, or alkoxy;
• R 13 is -Y-Z
• Y is selected from a bond, -CH 2 -, or -CH(Ci-C4 alkyl)-;
• X3 is S
• each R 21 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• each R 22 is independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl.
• Another embodiment provides a compound of Formula (XVII), wherein R A is
• Another embodiment provides a compound of Formula (XVII), wherein R A is
• Another embodiment provides a compound of Formula (XVII), wherein R A is
• Another embodiment provides a compound of Formula (XVII), wherein R is CH 3 .
• Another embodiment provides a compound of Formula (XVII), wherein X6 is C-H.
• Another embodiment provides a compound of Formula (XVII), wherein X6 is N.
• Another embodiment provides a compound of Formula (XVII), wherein X5 is C-R 5 .
• Another embodiment provides a compound of Formula (XVII), wherein X5 is N.
• Another embodiment provides a compound of Formula (XVII), wherein R 5 is hydrogen, halogen, or alkyl.
• Another embodiment provides a compound of Formula (XVII), wherein R 6 is hydrogen, halogen, or alkyl.
• Another embodiment provides a compound of Formula (XVII), wherein R 6 is heterocyclyl. Another embodiment provides a compound of Formula (XVII), wherein R 6 is cycloalkylalkynyl. Another embodiment provides a compound of Formula (XVII), wherein R 6 is alkoxy, cycloalkyloxy, or cycloalkylalkoxy.
• Another embodiment provides a compound of Formula (XVII), wherein Y is a bond.
• Another embodiment provides a compound of Formula (XVII), wherein Y is a -CH 2 -.
• Another embodiment provides a compound of Formula (XVII), wherein Z is -S0 2 R .
• Another embodiment provides a compound of Formula (XVII), wherein Z is -N(R )S0 2 R .
• Another embodiment provides a compound of Formula (XVII), wherein Z is -S0 2 N(R ) 2 .
• Another embodiment provides a compound of Formula (XVII), wherein Z is -
• R 21 is alkyl, cycloalkyl, or cycloalkylalkyl. Another embodiment provides a compound of
• Another embodiment provides a compound of Formula (XVII), wherein W is -O- and X is alkyl. Another embodiment provides a compound of Formula (XVII), wherein W is -O- and X is alkynyl. Another embodiment provides a compound of Formula (XVII), wherein W is -O- and X is aryl. Another embodiment provides a compound of Formula (XVII), wherein W is -O- and X is cycloalkylalkyl. Another embodiment provides a compound of Formula (XVII), wherein W is -O- and X is cycloalkylalkynyl. Another embodiment provides a compound of Formula (XVII), wherein the R 6 is CD 3 .

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Pyridine Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
• Other In-Based Heterocyclic Compounds (AREA)

Priority Applications (30)

Applications Claiming Priority (4)

Publications (1)

Family

ID=52826700

Family Applications (1)

Country Status (31)

Cited By (25)

Families Citing this family (34)

Citations (5)

Family Cites Families (65)

• 2014
  • 2014-10-17 ES ES19213205T patent/ES2930305T3/es active Active
  • 2014-10-17 LT LTEP14854531.2T patent/LT3057586T/lt unknown
  • 2014-10-17 HR HRP20221389TT patent/HRP20221389T1/hr unknown
  • 2014-10-17 SI SI201431508T patent/SI3057586T1/sl unknown
  • 2014-10-17 DK DK17175464.1T patent/DK3290407T3/da active
  • 2014-10-17 TW TW108143472A patent/TWI771630B/zh active
  • 2014-10-17 HU HUE19213205A patent/HUE060767T2/hu unknown
  • 2014-10-17 RS RS20221050A patent/RS63733B1/sr unknown
  • 2014-10-17 EP EP22197951.1A patent/EP4134364A3/en active Pending
  • 2014-10-17 EA EA201690734A patent/EA035727B1/ru not_active IP Right Cessation
  • 2014-10-17 SI SI201431523T patent/SI3290407T1/sl unknown
  • 2014-10-17 MX MX2016005038A patent/MX371386B/es active IP Right Grant
  • 2014-10-17 ES ES17175464T patent/ES2775217T3/es active Active
  • 2014-10-17 EP EP14854531.2A patent/EP3057586B1/en active Active
  • 2014-10-17 PT PT192132058T patent/PT3640241T/pt unknown
  • 2014-10-17 DK DK19213205.8T patent/DK3640241T3/da active
  • 2014-10-17 SG SG10201804471PA patent/SG10201804471PA/en unknown
  • 2014-10-17 ES ES14854531T patent/ES2774318T3/es active Active
  • 2014-10-17 CN CN201810570209.XA patent/CN108558889B/zh active Active
  • 2014-10-17 SG SG11201602996RA patent/SG11201602996RA/en unknown
  • 2014-10-17 PE PE2016000520A patent/PE20161065A1/es not_active Application Discontinuation
  • 2014-10-17 RS RS20200373A patent/RS60136B1/sr unknown
  • 2014-10-17 PT PT148545312T patent/PT3057586T/pt unknown
  • 2014-10-17 TW TW103136078A patent/TWI676619B/zh active
  • 2014-10-17 CA CA2927567A patent/CA2927567C/en active Active
  • 2014-10-17 CN CN201480069272.5A patent/CN105828820B/zh active Active
  • 2014-10-17 EP EP19213205.8A patent/EP3640241B1/en active Active
  • 2014-10-17 EP EP17175464.1A patent/EP3290407B1/en active Active
  • 2014-10-17 DK DK14854531.2T patent/DK3057586T3/da active
  • 2014-10-17 LT LTEP17175464.1T patent/LT3290407T/lt unknown
  • 2014-10-17 RS RS20200242A patent/RS60002B1/sr unknown
  • 2014-10-17 PL PL14854531T patent/PL3057586T3/pl unknown
  • 2014-10-17 KR KR1020167013057A patent/KR102311573B1/ko active IP Right Grant
  • 2014-10-17 FI FIEP19213205.8T patent/FI3640241T3/fi active
  • 2014-10-17 HU HUE17175464A patent/HUE048371T2/hu unknown
  • 2014-10-17 CA CA3148196A patent/CA3148196A1/en active Pending
  • 2014-10-17 PL PL19213205.8T patent/PL3640241T3/pl unknown
  • 2014-10-17 JP JP2016549208A patent/JP6445574B2/ja active Active
  • 2014-10-17 PL PL17175464T patent/PL3290407T3/pl unknown
  • 2014-10-17 PE PE2017002444A patent/PE20180248A1/es not_active Application Discontinuation
  • 2014-10-17 SI SI201431997T patent/SI3640241T1/sl unknown
  • 2014-10-17 US US14/517,705 patent/US9034900B2/en active Active
  • 2014-10-17 WO PCT/US2014/061261 patent/WO2015058160A1/en active Application Filing
  • 2014-10-17 BR BR112016008593-0A patent/BR112016008593B1/pt active IP Right Grant
  • 2014-10-17 CR CR20160229A patent/CR20160229A/es unknown
  • 2014-10-17 LT LTEP19213205.8T patent/LT3640241T/lt unknown
  • 2014-10-17 AU AU2014337064A patent/AU2014337064B2/en active Active
  • 2014-10-17 PT PT171754641T patent/PT3290407T/pt unknown
• 2015
  • 2015-03-13 US US14/658,048 patent/US9115114B2/en active Active
  • 2015-07-01 US US14/789,881 patent/US9598372B2/en active Active
• 2016
  • 2016-04-12 IL IL245074A patent/IL245074B/en active IP Right Grant
  • 2016-04-17 SA SA516370965A patent/SA516370965B1/ar unknown
  • 2016-04-18 CL CL2016000925A patent/CL2016000925A1/es unknown
  • 2016-04-18 PH PH12016500722A patent/PH12016500722A1/en unknown
  • 2016-04-18 NI NI201600056A patent/NI201600056A/es unknown
• 2017
  • 2017-02-17 US US15/436,340 patent/US10023592B2/en active Active
• 2018
  • 2018-01-16 IL IL256946A patent/IL256946B/en active IP Right Grant
  • 2018-02-05 CL CL2018000318A patent/CL2018000318A1/es unknown
  • 2018-05-25 US US15/990,576 patent/US10562915B2/en active Active
  • 2018-09-10 JP JP2018169146A patent/JP6734896B2/ja active Active
• 2019
  • 2019-02-26 AU AU2019201352A patent/AU2019201352B2/en active Active
• 2020
  • 2020-01-15 US US16/744,080 patent/US10941160B2/en active Active
  • 2020-02-28 HR HRP20200341TT patent/HRP20200341T1/hr unknown
  • 2020-02-28 CY CY20201100189T patent/CY1122734T1/el unknown
  • 2020-03-23 CY CY20201100274T patent/CY1122886T1/el unknown
  • 2020-03-25 HR HRP20200492TT patent/HRP20200492T1/hr unknown
  • 2020-12-31 US US17/139,963 patent/US11884680B2/en active Active
• 2023
  • 2023-12-06 US US18/531,630 patent/US20240182490A1/en active Pending

Patent Citations (5)

Also Published As

Similar Documents

Legal Events